Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02764541 |
|
Recruitment Status :
Active, not recruiting
First Posted : May 6, 2016
Last Update Posted : July 18, 2022
|
Sponsor:
Dana-Farber Cancer Institute
Collaborator:
Pfizer
Information provided by (Responsible Party):
Otto Metzger, Dana-Farber Cancer Institute
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
Results Submitted - Not Posted on ClinicalTrials.gov
Results information has been submitted to ClinicalTrials.gov by the sponsor or investigator, but is not yet
publicly available (or "posted") on ClinicalTrials.gov. The submitted information may not be available if it is pending
Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during
QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review
assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific
validity or relevance of the submitted information.
| Recruitment Status : | Active, not recruiting |
|---|---|
| Actual Primary Completion Date : | February 2022 |
| Estimated Study Completion Date : | April 2031 |
| Submission Cycle | Results Submitted to ClinicalTrials.gov | Results Returned after Quality Control Review |
|---|---|---|
| 1 |
February 15, 2023 | March 14, 2023 |
| 2 |
April 18, 2023 | May 10, 2023 |